Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Karla M Rada-PascualDepartamento de Fisiología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0001-6942-431X
Alejandra M Zúniga-MuñozDepartamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0002-0522-9395
Yamnia Q Alvarez-AlvarezDepartamento de Fisiología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.
Leonardo Del Valle-MondragónDepartamento de Farmacología "Dr. Rafael Méndez Martínez", Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0002-2999-1050
Ivan Rubio-GayossoSección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.ORCID 0000-0001-8315-8572
Constanza E Martínez-OlivaresSección de Patología Experimental, Departamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City 14080, Mexico.ORCID 0000-0001-5128-7695
Rogelio Hernández-PandoSección de Patología Experimental, Departamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City 14080, Mexico.ORCID 0000-0003-1292-3833
Horacio Osorio-AlonsoDepartamento de Fisiopatología Cardio-Renal, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0002-9238-4202
José L Sánchez-GloriaDivision of Nephrology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL 60612, USA.ORCID 0000-0002-2077-7007
Pedro L FloresDepartamento de Instrumentación Electromecánica, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0002-6836-6223
Julio SandovalDepartamento de Inmunología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0001-6825-3600
Jaime H Gómez-ZamudioUnidad de Investigación Médica en Bioquímica, Hospital de Especialidades "Bernardo Sepulveda", Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City 06720, Mexico.ORCID 0000-0002-4903-2420
Roxana CarbóDepartamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0002-3581-398X
Fausto Sánchez-MuñozDepartamento de Fisiología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0001-6556-1632
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
We evaluated the effects of fenofibrate (FF) in a SU5416/hypoxia model of pulmonary arterial hypertension (PAH) with a specific focus on its influence on the renin-angiotensin system (RAS). We assessed right ventricular systolic pressure (RVSP), mean pulmonary artery pressure (mPAP), medial pulmonary artery wall thickening, right ventricular (RV) hypertrophy, systolic pulmonary artery pressure (SPAP), pulmonary artery effective elastance (PAEa), RV diastolic pressure (RVDP), RV developed pressure (RVDevP), right ventricular-pulmonary arterial coupling index (RVPAC), RV dp/dt max and dp/dt min. Levels of angiotensin II, angiotensin (1-7), angiotensin-converting enzyme 2 (ACE2),
Indexed as
FenofibrateHypertension, PulmonaryPulmonary Arterial HypertensionRenin-Angiotensin SystemAngiotensin-Converting Enzyme 2Angiotensin IAngiotensin IIAnimalsBone Morphogenetic Protein Receptors, Type IIDisease Models, AnimalHypoxiaIndolesLungMalePeptide FragmentsPeptidyl-Dipeptidase AAce2 protein, ratAngiotensin-Converting Enzyme 2Angiotensin Iangiotensin I (1-7)Angiotensin IIBone Morphogenetic Protein Receptors, Type IIFenofibrateIndolesPeptide FragmentsPeptidyl-Dipeptidase AProto-Oncogene MasPyrrolesReceptor, Angiotensin, Type 1Receptors, G-Protein-CoupledSemaxinibfenofibratepulmonary arterial hypertensionrenin–angiotensin system
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Fenofibrate as a Modulator of the Renin-Angiotensin System in Su/Hx-Induced Pulmonary Arterial Hypertension. · full record | Socratic